Table 1

Baseline demographics and cohort characteristics before and up to 3 months after the third BNT162b2 dose

CharacteristicsN=97
Age
 Median (IQR), years70.0 (66‒74)
Sex, male, n (%)38 (39)
Comorbidities, n (%)
 Dyslipidaemia59 (61)
 Hypertension48 (49)
 Obesity26 (27)
 Diabetes19 (20)
 Ischaemic heart disease17 (18)
 Congestive heart failure1 (1)
Clinical Frailty Scale, n (%)
 Very fit (level 1)28 (29)
 Well (level 2)56 (58)
 Managing well (level 3)8 (8)
 Vulnerable (level 4)4 (4)
 Mildly frail (level 5)1 (1)
Analysis before the third dose (T0)
 Median (IQR) days after the first dose221 (218‒225)
 Median (IQR) IgG titres, AU/mL440 (294‒923)
Analysis 10–19 days after the third dose (T1)
 Median (IQR) days after the first dose236 (232‒240)
 Median (IQR) days after the third dose14 (14‒17)
 Median (IQR) IgG titres, AU/mL25 429 (14 203‒36 114)
Analysis 74–103 days after the third dose (T2)
 Median (IQR) days after the first dose316 (312‒320)
 Median (IQR) days after the third dose94 (92‒97)
 Median (IQR) IgG titres, AU/mL8306 (4595‒14 701)
 Median (IQR) neutralising antibody titre1294 (848‒2072)
  • AU, arbitrary units.